IL22RA1 and Hyperglycemia: No improvements in hyperglycemia or proinsulin/insulin levels were observed in these animals when treated with mIL-22-ScFv, confirming that IL-22ra1 β-cell signaling is critical for the improvements in glucose control (Fig. 5a).